Opinion in Ireland

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Exel: increasing its Accenture

Exel is partnering again with Accenture, to improve and develop better control and visibility of its European freight finance function. As manufacturers outsource more and more of their business to logistics providers (among others), it's becoming clear that logistics firms can find improvements and success in outsourcing their own operations.

Published By Datamonitor
21 Oct 2002
CommentWire
CommentWire

DCC/Centrica: LPG sale leaves both sides happy

Irish conglomerate DCC is now the second placed company in the UK LPG market, behind the dominant Calor and ahead of Shell Gas. Building on its acquisition of Alta Gas last year, DCC now has 21% of the market. Meanwhile, Centrica can focus more on direct client relationships - upselling additional services to its huge customer base.

Published By Datamonitor
04 Nov 2002
CommentWire
CommentWire

GM foods: give it time

After a five year long moratorium on growing and commercializing GM foods, the EU has authorized the entry of a GM product onto the market. European consumers are still unconvinced, and the biotechnology companies behind the products fear the public may reject them. However consumers may learn to accept GM, first in nutraceuticals, and then in mainstream foods.

Published By Datamonitor
02 Dec 2003
CommentWire
CommentWire

Elan: Antegren offers renewed hope for growth

Elan [ELN] and Biogen [BIIB] have announced that the Phase III maintenance trial of Antegren in Crohn's disease met the primary end-point of maintenance of response. The new data improves the chance of regulatory approval for Antegren, but the product may still need to find a role in inducing Crohn's disease remission to boost the fortunes of struggling Elan.

Published By Datamonitor
02 Feb 2004
CommentWire
CommentWire

Elan/Biogen: MS players cower as Antegren looms

Shares of Biogen [BIIB] and Elan [ELN] jumped after they announced they would apply for FDA approval of Antegren for multiple sclerosis treatment ahead of schedule. Antegren is crucial for maintaining Biogen's market share as it is facing stiff competition from Serono's [SRA] Rebif in the US. The drug is equally vital to Elan, which in recent years has suffered numerous financial setbacks.

Published By Datamonitor
19 Feb 2004
CommentWire
CommentWire

Ryanair: fight back not pay back

The European Commission has ruled that some of the subsidies Ryanair [RYA.L] received from a Belgian airport are illegal. The decision could threaten low-cost airlines' deals with regional airports and affect Ryanair's own expansion plans. Furthermore, it could become a weapon in the hands of high fare airlines to obstruct competition in Europe.

Published By Datamonitor
26 May 2004
CommentWire
CommentWire

Fuel retail: Ireland gears up for first motorway service stations

Several new motorway service stations are expected to open on the Emerald Isle over the next couple of years, and leading petrol retailers such as Statoil [STL.OL], Esso and Texaco would be foolish not to seize this fresh opportunity to capture a larger share of the Irish market for both fuel and non-fuel products.

Published By Datamonitor
25 Aug 2004
CommentWire
CommentWire

Bord Gais: there's no place like home

While Bord Gais takes the first step towards aggressively tackling the UK market, gains to be made back home cannot be ignored. In the lull after Ireland's final move towards liberalization, Bord Gais must seize the moment to reap rewards and protect its position before other European power suppliers arrive on Irish shores.

Published By Datamonitor
13 Oct 2004
CommentWire
CommentWire

Irish electricity: market opening in name alone

The electricity market opening mechanism introduced in Ireland is based on supplementing independent power producer (IPP) capacity with released capacity from monopoly ESB (virtual IPP), so that new entrants have the volumes to supply customers. Initially, enough IPP and discounted VIPP capacity was available for new entrants, but there is not yet enough for full market opening in 2005.

Published By Datamonitor
05 Jan 2005
Expert View
Expert View

Testing times for Tysabri

Biogen Idec and Elan have announced the voluntary suspension from sale and withdrawal from clinical trials of Tysabri, the companies' novel therapy for the treatment of relapse remitting multiple sclerosis (RRMS). This move has already slashed share prices of both companies. Even if Tysabri is relaunched with some form of black-box warning, doubts will surely linger over its long-term safety.

Published By Datamonitor
01 Mar 2005

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.